Novo Nordisk's 2026 Q3 earnings exceed $2.1B from Wegovy sales

The oral Wegovy pill's UK launch is expected to drive strong Q3 revenue for Novo Nordisk, with private sales likely offsetting lagging NHS adoption. Analysts project semaglutide-based drugs to contribute over 25% of total revenue.

earnings · Prediction Market

Implied probability (Yes)

72%

Closes

2026-10-31

More earnings markets

• Forum AI raises $50M+ in Series B funding by 2027-03-31 — 60% Yes
• Anthropic's compute deal with xAI will underperform revenue targets by Q4 2026 — 70% Yes
• Titleist sells more clubs than Callaway in 2026 — 72% Yes
• Sadi Thermal Machines secures $50M+ funding round by 2027 — 70% Yes
• Lime achieves profitability within 12 months post-IPO — 55% Yes
• SK Hynix ADRs to price at or above midpoint range by July 10 — 75% Yes
• Flexjet stock rises 15% by Q4-2027 on fuel cost advantage — 70% Yes
• Driving instructor revenue drops 15% in Q3 2027 due to test booking changes — 68% Yes

Browse all earnings markets →